{"id":62374,"date":"2025-12-17T19:05:52","date_gmt":"2025-12-17T18:05:52","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/"},"modified":"2025-12-17T19:05:52","modified_gmt":"2025-12-17T18:05:52","slug":"femhealth-ventures-closes-oversubscribed-65-million-fund-ii","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/","title":{"rendered":"FemHealth Ventures Closes Oversubscribed $65 Million Fund II"},"content":{"rendered":"
\n

SHORT HILLS, N.J.–(BUSINESS WIRE)–#healthcare<\/a>–FemHealth Ventures, a leading women\u2019s health-focused venture capital firm, a top-decile performer across DPI and IRR for Fund I, announced the close of FemHealth Ventures Fund II at $65 million. The oversubscribed raise brings the firm\u2019s assets under management to $100 million across two funds and further solidifies FemHealth Ventures\u2019 position as a category-defining investor in women\u2019s health innovation.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe fund received significant support from existing limited partners alongside new investors aligned with the firm\u2019s mission to transform women\u2019s health while achieving exceptional financial returns. FemHealth Ventures Fund I, launched in 2021, is recognized as a top-decile performer across DPI and IRR according to Carta and Pitchbook databases.\n<\/p>\n

\n\u201cWe are thrilled to announce the successful close of Fund II, more than doubling the size of our inaugural fund,\u201d said Maneesha Ghiya, Managing Partner of FemHealth Ventures. \u201cThis raise reflects growing recognition that women\u2019s health innovation offers both substantial societal impact and compelling investment potential. We are grateful for the trust our limited partners continue to place in us.\u201d\n<\/p>\n

\nFemHealth Ventures is widely recognized for establishing the industry\u2019s three-category framework defining women\u2019s health as conditions that appear only in women, mostly in women, or differently in women. First introduced in 2019 as part of the FemHealth Framework (\u00a9 2019 FemHealth Ventures), this model is now widely used across the sector to guide research, strategy, and investment.\n<\/p>\n

\n\u201cThe next generation of transformative women\u2019s health companies will be led by visionary founders, and we are honored to support them,\u201d added Sara Crown Star, Venture Partner at FemHealth Ventures.\n<\/p>\n

\nFund II will continue investing across drugs, devices, diagnostics, and digital \/ AI-enabled technologies that address unmet needs in women\u2019s health. Fund II remains focused on partnering with exceptional founders who are building solutions that materially improve lives.\n<\/p>\n

\nAbout FemHealth Ventures<\/b>\n<\/p>\n

\nFemHealth Ventures is a women\u2019s health\u2013focused venture capital firm investing in breakthrough innovations that deliver meaningful health advances and strong investor returns. The firm has been featured in Forbes<\/i>, The Wall Street Journal<\/i>, Insider<\/i>, and CNBC<\/i> and manages $100 million in assets.\n<\/p>\n

\nFor more information, visit www.femhealthventures.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact<\/b>
Email: info@femhealthventures.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SHORT HILLS, N.J.–(BUSINESS WIRE)–#healthcare–FemHealth Ventures, a leading women\u2019s health-focused venture capital firm, a top-decile performer across DPI and IRR for Fund I, announced the close of FemHealth Ventures Fund II at $65 million. The oversubscribed raise brings the firm\u2019s assets under management to $100 million across two funds and further solidifies FemHealth Ventures\u2019 position as … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62374","6":"format-standard","7":"category-industry"},"yoast_head":"\nFemHealth Ventures Closes Oversubscribed $65 Million Fund II - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FemHealth Ventures Closes Oversubscribed $65 Million Fund II - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SHORT HILLS, N.J.–(BUSINESS WIRE)–#healthcare–FemHealth Ventures, a leading women\u2019s health-focused venture capital firm, a top-decile performer across DPI and IRR for Fund I, announced the close of FemHealth Ventures Fund II at $65 million. The oversubscribed raise brings the firm\u2019s assets under management to $100 million across two funds and further solidifies FemHealth Ventures\u2019 position as ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-17T18:05:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251217420341\/en\/2672633\/22\/femhealth-logo-cobalt_300.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"FemHealth Ventures Closes Oversubscribed $65 Million Fund II\",\"datePublished\":\"2025-12-17T18:05:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\\\/\"},\"wordCount\":371,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251217420341\\\/en\\\/2672633\\\/22\\\/femhealth-logo-cobalt_300.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\\\/\",\"name\":\"FemHealth Ventures Closes Oversubscribed $65 Million Fund II - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251217420341\\\/en\\\/2672633\\\/22\\\/femhealth-logo-cobalt_300.jpg\",\"datePublished\":\"2025-12-17T18:05:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251217420341\\\/en\\\/2672633\\\/22\\\/femhealth-logo-cobalt_300.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251217420341\\\/en\\\/2672633\\\/22\\\/femhealth-logo-cobalt_300.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FemHealth Ventures Closes Oversubscribed $65 Million Fund II\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FemHealth Ventures Closes Oversubscribed $65 Million Fund II - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/","og_locale":"en_US","og_type":"article","og_title":"FemHealth Ventures Closes Oversubscribed $65 Million Fund II - Pharma Trend","og_description":"SHORT HILLS, N.J.–(BUSINESS WIRE)–#healthcare–FemHealth Ventures, a leading women\u2019s health-focused venture capital firm, a top-decile performer across DPI and IRR for Fund I, announced the close of FemHealth Ventures Fund II at $65 million. The oversubscribed raise brings the firm\u2019s assets under management to $100 million across two funds and further solidifies FemHealth Ventures\u2019 position as ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/","og_site_name":"Pharma Trend","article_published_time":"2025-12-17T18:05:52+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251217420341\/en\/2672633\/22\/femhealth-logo-cobalt_300.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"FemHealth Ventures Closes Oversubscribed $65 Million Fund II","datePublished":"2025-12-17T18:05:52+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/"},"wordCount":371,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251217420341\/en\/2672633\/22\/femhealth-logo-cobalt_300.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/","url":"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/","name":"FemHealth Ventures Closes Oversubscribed $65 Million Fund II - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251217420341\/en\/2672633\/22\/femhealth-logo-cobalt_300.jpg","datePublished":"2025-12-17T18:05:52+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251217420341\/en\/2672633\/22\/femhealth-logo-cobalt_300.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251217420341\/en\/2672633\/22\/femhealth-logo-cobalt_300.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/femhealth-ventures-closes-oversubscribed-65-million-fund-ii\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"FemHealth Ventures Closes Oversubscribed $65 Million Fund II"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62374","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62374"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62374\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62374"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62374"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62374"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}